Hypoglycemia News and Research

RSS

Hypoglycemia, also called low blood glucose or low blood sugar, occurs when blood glucose drops below normal levels. Glucose, an important source of energy for the body, comes from food. Carbohydrates are the main dietary source of glucose.

Study finds that triple therapy corrects two core defects in type 2 diabetes

Patients with type 2 diabetes fare significantly better if they are started on three medications at the time of diagnosis than if they are prescribed a single drug and have other therapies added later, a San Antonio researcher said June 22 at the 73rd Scientific Sessions of the American Diabetes Association in Chicago.

25 Jun 2013

Patients with type2 diabetes, renal impairment have less hypoglycemia with JANUVIA compared to sulfonylurea

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced results from a post-hoc pooled analysis showing patients with type 2 diabetes and mild renal impairment treated with JANUVIA- (sitagliptin) 100 mg once-daily achieved similar blood sugar reductions as those treated with the sulfonylureas glipizide or glimepiride, with significantly fewer events of hypoglycemia (low blood sugar), and with weight loss instead of weight gain.

24 Jun 2013

Sanofi reports Phase 3 study of insulin U300 shows better blood sugar control than Lantus

Sanofi announced today that the first Phase 3 study results for its investigational new insulin U300 showed equivalent blood sugar control with fewer night-time low blood sugar events compared to Lantus.

24 Jun 2013

Linagliptin significantly reduces blood glucose levels in T2D patients with moderate to severe renal impairment

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company today announced results from a new study in which linagliptin demonstrated statistically significant reductions in blood glucose levels (HbA1c) after 12 weeks (the study's primary endpoint) in adults with type 2 diabetes (T2D) with moderate to severe renal impairment, compared with placebo. Most patients had T2D for more than ten years (76 percent) and were on insulin (86 percent).

24 Jun 2013

Sanofi presents positive phase 3 data for GLP-1 receptor for type 2 diabetes

Sanofi US (EURONEXT: SAN and NYSE: SNY) announced today data that showed lixisenatide, an investigational once-daily prandial glucagon-like peptide 1 (GLP-1) receptor agonist, decreased HbA1c by reducing PPG (postprandial glucose) daytime exposure when added to standard of care which includes basal insulin with or without oral anti-diabetic agents (OADs). Lixisenatide is for the treatment of adults with type 2 diabetes mellitus.

24 Jun 2013

New data suggest PaQ device can reduce known barriers to insulin therapy among people with type 2 diabetes

CeQur SA, a company focused on the development and commercialization of simple insulin delivery devices, announced that comprehensive data from a study of the company's PaQ Insulin Delivery Device will be presented today and tomorrow at the American Diabetes Association 73rd Scientific Sessions in Chicago, IL. The data suggest that PaQ can reduce known barriers to insulin therapy among people with type 2 diabetes, potentially improving their glycemic control.

24 Jun 2013

Bristol-Myers Squibb and AstraZeneca announce top line results of Phase 4 SAVOR-TIMI-53 clinical trial of Onglyza

Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN) today announced top line results of the Phase 4 SAVOR-TIMI-53 (Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus) clinical trial of Onglyza ® (saxagliptin).

20 Jun 2013

Insulin degludec has reduced risk of recurrent hypoglycemia than insulin glargine

Insulin degludec (Tresiba), a new ultra-long-acting insulin, has a similar or reduced risk of recurrent hypoglycemia—low blood sugar—compared with the commercially available insulin glargine, a new meta-analysis study finds.

19 Jun 2013

Diabetes may increase risk for developing Alzheimer’s and vascular dementia

A study of older adults with diabetes mellitus (DM) suggests a bidirectional association between hypoglycemic (low blood glucose) events and dementia, according to a report published Online First by JAMA Internal Medicine, a JAMA Network publication.

12 Jun 2013

CREON Delayed-Release Capsules now available in US for patients with EPI

AbbVie announced that a new, higher-dose capsule of CREON (pancrelipase) Delayed-Release Capsules is commercially available in the United States. The U.S. Food and Drug Administration recently approved CREON in a 36,000 lipase-unit dose to treat patients with exocrine pancreatic insufficiency due to cystic fibrosis, swelling of the pancreas that lasts a long time (chronic pancreatitis), removal of some or all of the pancreas (pancreatectomy), or other conditions.

31 May 2013

New evidence shows intensive insulin therapy does not provide substantial benefits

High blood glucose is associated with poor outcomes in hospitalized patients, and use of intensive insulin therapy (IIT) to control hyperglycemia is a common practice in hospitals. But the recent evidence does not show a consistent benefit and even shows harms associated with the use of IIT, according to the American College of Physicians' (ACP) Clinical Guidelines Committee in a new evidence-based paper published today online in the American Journal of Medical Quality.

24 May 2013

Lexicon Pharmaceuticals advances Phase 2 clinical trial of LX4211 in patients with type 1 diabetes

Lexicon Pharmaceuticals, Inc. announced today that it is progressing into the placebo-controlled portion of its Phase 2 clinical trial of LX4211 in patients with type 1 diabetes, having successfully completed the open-label, pioneer portion of the trial.

10 May 2013

Researchers develop new method for continuous glucose monitoring in patients with type 1 diabetes

Researchers at the Universitat Politècnica de València and the Universitat de Girona have developed a new method for continuous glucose monitoring in patients with type 1 diabetes.

8 May 2013

Pancreatitis and diabetes drugs: an interview with Dr Sonal Singh, Johns Hopkins University School of Medicine

Acute pancreatitis is an inflammation of the pancreas which leads to leakage of pancreatic enzymes. Apart from certain drugs such as GLP-1 based therapies, the most common causes of pancreatitis are Gallstones and Alcohol use.

30 Apr 2013

Merck, Pfizer sign collaboration agreement for development and commercialization of ertugliflozin

Merck & Co., Inc., known as MSD outside the United States and Canada, and Pfizer Inc. today announced that they have entered into a worldwide (except Japan) collaboration agreement for the development and commercialization of Pfizer's ertugliflozin (PF-04971729), an investigational oral sodium glucose cotransporter (SGLT2) inhibitor being evaluated for the treatment of type 2 diabetes.

From Pfizer, Inc. 30 Apr 2013

AACE publishes comprehensive diabetes management algorithm to treat prediabetes, T2DM patients

The American Association of Clinical Endocrinologists today announced the publication of its comprehensive diabetes management algorithm created to guide primary care physicians, endocrinologists and other health care professionals in the treatment of prediabetes and type 2 diabetes mellitus patients.

20 Apr 2013

Hypoglycemia News and Research

Further Reading

Study finds that triple therapy corrects two core defects in type 2 diabetes

Patients with type2 diabetes, renal impairment have less hypoglycemia with JANUVIA compared to sulfonylurea

Sanofi reports Phase 3 study of insulin U300 shows better blood sugar control than Lantus

Linagliptin significantly reduces blood glucose levels in T2D patients with moderate to severe renal impairment

Sanofi presents positive phase 3 data for GLP-1 receptor for type 2 diabetes

New data suggest PaQ device can reduce known barriers to insulin therapy among people with type 2 diabetes

Bristol-Myers Squibb and AstraZeneca announce top line results of Phase 4 SAVOR-TIMI-53 clinical trial of Onglyza

Insulin degludec has reduced risk of recurrent hypoglycemia than insulin glargine

Diabetes may increase risk for developing Alzheimer’s and vascular dementia

CREON Delayed-Release Capsules now available in US for patients with EPI

New evidence shows intensive insulin therapy does not provide substantial benefits

Lexicon Pharmaceuticals advances Phase 2 clinical trial of LX4211 in patients with type 1 diabetes

Researchers develop new method for continuous glucose monitoring in patients with type 1 diabetes

Pancreatitis and diabetes drugs: an interview with Dr Sonal Singh, Johns Hopkins University School of Medicine

Merck, Pfizer sign collaboration agreement for development and commercialization of ertugliflozin

AACE publishes comprehensive diabetes management algorithm to treat prediabetes, T2DM patients

HUGO recognizes Dr. Patrick Tan for research on genomic profiles of Asian cancers

Research sheds new light on role of ATRX mutations in brain and pituitary

Case Western Reserve University receives grant to research on glucose-responsive insulin

Artificial pancreas outperforms insulin pump in diabetes camp

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News